Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zhongyuan Union Cell & Gene Engineering (SHSE:600645) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Zhongyuan Union Cell & Gene Engineering Receivables Turnover Related Terms
Zhongyuan Union Cell & Gene Engineering Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhongyuan Union Cell & Gene Engineering Receivables Turnover Chart
Zhongyuan Union Cell & Gene Engineering Annual Data
SHSE:600645 vs VRTX, REGN, RVMD: Receivables Turnover Comparison
For the Biotechnology subindustry, Zhongyuan Union Cell & Gene Engineering's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhongyuan Union Cell & Gene Engineering Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zhongyuan Union Cell & Gene Engineering's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Zhongyuan Union Cell & Gene Engineering's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhongyuan Union Cell & Gene Engineering (SHSE:600645) has a Receivables Turnover of 0.53 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Zhongyuan Union Cell & Gene Engineering and its competitors. According to the industry distribution chart, Zhongyuan Union Cell & Gene Engineering ranks #697 out of 843 companies in the Biotechnology industry, placing it in the top 82.7%.
Is Zhongyuan Union Cell & Gene Engineering's Receivables Turnover too high?
Zhongyuan Union Cell & Gene Engineering's current Receivables Turnover is 0.53. The Biotechnology industry median Receivables Turnover is 5.27. Zhongyuan Union Cell & Gene Engineering's value of 0.53 is 89.9% below this industry median. Based on the distribution chart, Zhongyuan Union Cell & Gene Engineering ranks #697 out of 843 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Zhongyuan Union Cell & Gene Engineering has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Zhongyuan Union Cell & Gene Engineering's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zhongyuan Union Cell & Gene Engineering ranks #697 out of 843 companies for Receivables Turnover. This places Zhongyuan Union Cell & Gene Engineering in the lower half of its industry. The industry median Receivables Turnover is 5.27. Zhongyuan Union Cell & Gene Engineering's value of 0.53 is 89.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 843 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhongyuan Union Cell & Gene Engineering's current Receivables Turnover of 0.53 is 89.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Zhongyuan Union Cell & Gene Engineering and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhongyuan Union Cell & Gene Engineering's current Receivables Turnover is 0.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhongyuan Union Cell & Gene Engineering stock overvalued right now?
Based on GuruFocus' analysis, Zhongyuan Union Cell & Gene Engineering (SHSE:600645) is currently considered Fairly Valued. The stock's GF Value™ is ¥20.85, compared to a current price of ¥22.33 — trading 7.1% above its estimated fair value. The current Receivables Turnover is 0.53 and 89.9% below the Biotechnology industry median of 5.27. Zhongyuan Union Cell & Gene Engineering's overall GF Score™ is 65/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Zhongyuan Union Cell & Gene Engineering (SHSE:600645), the current Receivables Turnover is 0.53 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhongyuan Union Cell & Gene Engineering (SHSE:600645) Overvalued in 2026?
Based on GuruFocus' analysis, Zhongyuan Union Cell & Gene Engineering stock appears to be overvalued.
The current stock price of ¥22.33 is trading 7.1% above its estimated GF Value™ of ¥20.85.
GuruFocus considers Zhongyuan Union Cell & Gene Engineering to be Fairly Valued.
Key valuation signals for SHSE:600645:
Receivables Turnover: 0.53
GF Value™: ¥20.85 vs. price of ¥22.33 (7.1% above fair value)
Industry Position: 89.9% below the Biotechnology median (#697 of 843)
No single metric tells the full story. See the SHSE:600645 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhongyuan Union Cell & Gene Engineering Corp Ltd is engaged in stem cell technology research, as well as detection and storage sources of stem cells in China. The company insists on the core strategy upon dual-core development of 'cell + gene' with the major businesses covering various cell storage businesses of newborns and adults; the preparation and storage of cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, adipose-derived stem cells and immune cells; genetic testing services relating to children's genes.
65GF Score
Get the complete analysis for SHSE:600645
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600645 has been successfully added to your 
